It seems that not only Solid, but also Pfizer and Sarepta, are...

It seems that not only Solid, but also Pfizer and Sarepta, are seeking to use AAVs to deliver versions of dystrophin to treat DMD.

The problem is that to reach large amounts of muscle or cross the blood-brain barrier, very high AAV quantities are required. And i.v. delivery of AAV vectors at high doses has been shown in recent animal studies to lead to systemic and sensory neuron toxicity.

Could PYC’s CCP approach solve the problem? Results of a mouse-model study at University of Washington suggests that it's possible. The UW researchers successfully demonstrated the successful (TAxI) peptide-mediated delivery of a recombinant protein (Cre) into motor neurons in the spinal cord following injection into the muscle. And they even compared the results of their TAxI peptide with TAT!

The UW researchers believe they have identified a promising new strategy for drug delivery to the CNS which could potentially lead to better and less invasive treatments for neurodegenerative diseases.

My question is, does PYC have a peptide that can outshine TAxI?

https://www.the-scientist.com/?arti...ted-in-High-Dose-AAV-Gene-Therapy-in-Animals/

https://www.biocentury.com/biocentu...es-wilson’s-findings-aav-toxicity-should-have-

https://www.liebertpub.com/doi/abs/10.1089/hum.2018.015

http://www.pnas.org/content/113/9/2514

https://bioe.uw.edu/taxi-peptide-motor-neuron-treatment-strategy/